Evidence map›Paper›PMID 36762472›Full record

ArticleActa oncologica (Stockholm, Sweden)2023

Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway.

T E Robsahm, K M Tsuruda, H H Hektoen, A H Storås, M B Cook, L M Hurwitz, H Langseth

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

T E RobsahmDepartment of Research, Cancer Registry of Norway, Oslo, Norway.ORCID 0000-0002-1652-7734
K M TsurudaDepartment of Research, Cancer Registry of Norway, Oslo, Norway.ORCID 0000-0001-8749-6237
H H HektoenDepartment of Research, Cancer Registry of Norway, Oslo, Norway.ORCID 0000-0002-2002-0944
A H StoråsDepartment of Research, Cancer Registry of Norway, Oslo, Norway.ORCID 0000-0002-9376-9163
M B CookDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0002-0533-7302
L M HurwitzDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0001-8932-5028
H LangsethDepartment of Research, Cancer Registry of Norway, Oslo, Norway.ORCID 0000-0002-9446-4855
Cancer Registry of Norway · NONational Cancer Institute · USOslo University Hospital · NO

Funding

Prostate Cancer StudiesZIACP010180 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBANES, DEMETRIUS · 2009 to 2025
$9.9M
Intramural NIH HHS ZIA CP010180
6 · The paper itself

Abstract

backgroundThe Prostate Cancer Cohort Consortium (PC3) Working Group proposed a definition for aggressive prostate cancer (PC) for aetiologic epidemiologic research. We aimed to validate this definition as well as a second approach utilising only information on stage at diagnosis.

methodsFirst primary PCs diagnosed 2004 - 2009 in the population-based Janus Serum Bank (JSB) cohort were identified by linkage to the population-based Cancer Registry of Norway (CRN) (

resultsOverall, 555 died from PC within 10 years. Approach 1 classified 24.7% of cases as aggressive and 13.6% were unclassified due to missing information. Approach 2 classified 19.6% as aggressive and 29% were unclassified. Sensitivity was highest for Approach 1 (0.76, 95% CI: 0.72 - 0.80 vs 0.69, 95% CI: 0.64 - 0.73), while PPVs were similar for both approaches (0.43, 95% CI: 0.40 - 0.46 and 0.40, 95% CI: 0.36 - 0.44). We observed similarly high sensitivity and higher PPVs than those reported by the PC3 Working Group.

conclusionsThe proposed definition of aggressive PC was applicable and valid in the JSB cohort. Stage at diagnosis can be useful if data on cTNM or Gleason score is unavailable.

Indexed as

Prostatic NeoplasmsHumansMaleNeoplasm GradingProstateProstate-Specific AntigenRegistriesProstate-Specific Antigenaggressive prostate cancerClassificationpopulation-based cohortregistry data

Identifiers

PMID36762472
PMCPMC10301241
OpenAlexW4319827797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.